Hi Peeteepoo and Moreforme, some very interesting information below.
Jocelyn Tan-Shalaby, MD2017
Glucose normally stimulates pancreatic β cells to release insulin, which allows glucose to enter cells and provide energy. With high carbohydrate and glucose intake, the pancreas increasingly secretes more insulin, which promotes the interaction of growth hormone receptors and growth hormones to produce insulin-like growth factor 1 (IGF-1) in the liver—promoting cell growth and proliferation, which can be detrimental to patients with cancer.
Anecdotal evidence state that many cancer cells use aerobic glycolysis and fermentation of pyruvate to lactate as a main source of energy… it is theorized that feeding a low-carbohydrate diet could effectively starve cancer cells through a decrease in the supply of glucose. However, despite the fact that this theory has been in existence for nearly a century, minimal data have been published to support the tangible benefits of low-carbohydrate diets for any species of animal with cancer.
Low Carbohydrate Diets in Cancer Therapeutics: Current EvidenceChristopher Haskins et al 2021
state " There is currently a paucity of evidence to suggest that a low-carbohydrate diet amongst a general population of cancer patients will improve cure rates"
Peeteepoo the jury is out. But in saying that , there has been no clinical studies in canines which I could find to agree or disagree.
There is a plethora of literature ( non studies) to support their hypothesis but clinically its devoid of true analysis.
----------------------------- Africa’s low COVID-19 mortality rate: A paradox? Lawal 2021
Their conclusions :Africa’s lower COVID-19 mortality rate is due to the lower population mean age, lower life expectancy, lower pre-COVID-19 era ‘65yr+ mortality rate’, and smaller pool of people surviving and living with cardiovascular diseases
But what about the parasites and do they affect SARS-CoV-19.
Effect of co-infection with intestinal parasites on COVID-19 severity: A prospective observational cohort studyDawit Wolday et al. 2021
state : Parasite co-infection is associated with a reduced risk of severe COVID-19 in African patients. Parasite-driven immunomodulatory responses may mute hyper-inflammation associated with severe COVID-19"
Again another hypothesis that is getting close to the mark.
Why COVID-19 is not so spread in Africa: How does Ivermectin affect it?Hisaya Tanioka, 2021
Also states "Scientists have so far been unable to determine the reason for the low number of COVID-19 cases in Africa"Conclusions The morbidity and mortality in the onchocerciasis endemic countries are lesser than those in the non-endemic ones. The community-directed onchocerciasis treatment with ivermectin is the most reasonable explanation for the decrease in morbidity and fatality rate in Africa. In areas where ivermectin is distributed to and used by the entire population, it leads to a significant reduction in mortality.
So Peeteepoo who knows, but agree there is a link .
-----------------------------
Hi Moreforme ,
Does MPL have a role in cardiac medication. Very intuitive, well done and well spotted. Have a read on this, email RA tell him, it's within patent time parameters for PAA my estimate. Go for it !
I have never researched this or seen this before and maybe it fits the PAA patent box.
The study was too large to copy and paste via HC standards.
Modulation of mTOR Signaling in Cardiovascular Disease to Target Acute and Chronic InflammationMadlen Kaldirim et al June 2022 .
Inflammation is a key component in the pathogenesis of cardiovascular diseases causing a significant burden of morbidity and mortality worldwide. Recent research shows that mammalian target of rapamycin (mTOR) signaling plays an important role in the general and inflammation-driven mechanisms that underpin cardiovascular disease. mTOR kinase acts prominently in signaling pathways that govern essential cellular activities including growth, proliferation, motility, energy consumption, and survival. Since the development of drugs targeting mTOR, there is proven efficacy in terms of survival benefit in cancer and allograft rejection. This review presents current information and concepts of mTOR activity in myocardial infarction and atherosclerosis, two important instances of cardiovascular illness involving acute and chronic inflammation.
(20min delay)